Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary

Does Concomitant Use of Methotrexate with JAK Inhibition Confer Benefit for Cardiovascular Outcomes? A Commentary

Abstract This commentary explores the potential cardiovascular (CV) benefits of combining methotrexate (MTX) and Janus kinase inhibitors (JAKis) in the treatment of rheumatoid arthritis (RA). While European guidelines recommend MTX as first-line treatment, concerns about the CV risks associated with...

Full description

Saved in:
Bibliographic Details
Main Authors: Peter C. Taylor, Alejandro Balsa, Anne-Barbara Mongey, Mária Filková, Myriam Chebbah, Solenn Le Clanche, Linda A. W. Verhagen, Torsten Witte, Daniela Opris-Belinski, Hubert Marotte, Jérôme Avouac
Format: Article
Language:English
Published: Adis, Springer Healthcare 2024-10-01
Series:Rheumatology and Therapy
Subjects:
Rheumatoid arthritis
Combination therapy
Methotrexate
Janus kinase inhibitors
Cardiovascular
Online Access:https://doi.org/10.1007/s40744-024-00721-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s40744-024-00721-x

Similar Items